Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation

Gut

Volumn 55, Issue 6, 2006, Pages 863-868

  Tapirdamaz, O ^a   Pravica, V ^b   Metselaar, H J ^a   Hansen, B ^a   Moons, L ^a   Van Meurs, J B J ^a   Hutchinson, I V ^b   Shaw, J ^c   Agarwal, K ^d   Adams, D H ^c   Day, C P ^d   Kwekkeboom, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ACUTE GRAFT REJECTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HOMOZYGOTE; HUMAN; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ACUTE DISEASE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAFT REJECTION; HAPLOTYPES; HUMANS; LIVER TRANSPLANTATION; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 33646772148     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.080937     Document Type: Article

References (24)

1. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol 1997;158:1989-93.
2. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-40.
3. Sanchez-Fueyo A, Weber M, Domenig C, et al. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol 2002;168:2274-81.
4. Magisrrelli G, Jeannin P, Herbault N, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999;29:3596-o02.
5. Oaks MK, Hallett KM, Penwell RT, et al. A native soluble form of CTLA-4. Cell Immunol 2000;201:144-53.
6. Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015-18.
7. Kouki T, Sawai Y, Gardine CA, et al. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function or CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.
8. Donner H, Rau H, Walfish PG, et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;82:143-6.
9. Agarwal K, Jones DE, Daly AK, et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-41.
10. Agarwol K, Czaja AJ, Jones DE, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53.
11. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11.
12. Anjos SM, Tessier MC, Polychronakos C. Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J Clin Endocrinol Metab 2004;89:6257-65.
13. Thio CL, Mosbruger TL, Kaslow RA, et al. Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol 2004;78:11258-62.
14. Fecteau S, Basadonna GP, Freitas A, et al. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2001;2:58-63.
15. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52.
16. de Reuver P, Pravica V, Hop W, et al. Recipient ctla-4+49 G/G genotype is associated with reduced incidence of acute rejection after liver transplantation. Am J Transplant 2003;3:1587-94.
17. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
18. Anjos S, Nguyen A, Ounissi-Benkalha H, et al. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002;277:46478-86.
19. Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996;157:4762-70.
20. Slavcheva E, Albanis E, Jiao Q, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms and susceptibility to acute allograft rejection. Transplantation 2001;72:935-40.
21. Marder BA, Schroppel B, Lin M, et al. The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. Am J Transplant 2003;3:424-31.
22. Farges O, Saliba F, Farhamant H, et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996;23:240-8.
23. Kwekkeboom J, Tha-In T, Tra WM, et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005;5:2393-402.
24. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-45.